Customize your JAMA Network experience by selecting one or more topics from the list below.
Antimicrobial resistance to existing therapies has made Helicobacter pylori infection increasingly difficult to treat. In a phase 3 trial published in the Annals of Internal Medicine, a 3-drug combination of amoxicillin, omeprazole, and rifabutin in 1 capsule achieved high eradication rates of H pylori infection.
The study’s 455 treatment-naive adults with confirmed H pylori infection were randomly assigned to receive the novel study drug or high-dose amoxicillin and omeprazole dual therapy for 14 days.
Four weeks after the treatment ended, H pylori was eradicated in 83.8% of patients who received the rifabutin-based triple therapy compared with 57.7% in the omeprazole and amoxicillin group. The microbe’s resistance to clarithromycin or metronidazole did not affect eradication rates, and no rifabutin resistance was detected.
Slomski A. Novel Therapy Eradicates H pylori. JAMA. 2020;324(4):327. doi:10.1001/jama.2020.12592
Coronavirus Resource Center
Create a personal account or sign in to: